Discovery of a role of the novel hepatokine, hepassocin, in obesity

Ru Lai Huang, Chung Hao Li, Ye Fong Du, Kai Pi Cheng, Ching Han Lin, Che Yuan Hu, Jin Shang Wu, Chih Jen Chang, Hung Tsung Wu, Horng Yih Ou

研究成果: 雜誌貢獻文章

摘要

Obesity is a public health problem that has raised concerns worldwide and is often associated with hepatic steatosis. Hepassocin is a novel hepatokine that causes hepatic steatosis and induces insulin resistance (IR). However, the role of hepassocin in obesity remains obscure. Thus, the aim of this study was to investigate the relationship between hepassocin levels and obesity. In total, 371 subjects who had a normal weight (NW), were overweight, or were obese were enrolled. We found that hepassocin levels in subjects who were overweight (6,705 ± 1,707 pg/ml) or obese (7,335 ± 2,077 pg/ml) were significantly higher than those of subjects with a NW (5,767 ± 1,500 pg/ml) (p <.001, test for trend). A multiple linear regression analysis showed that the body-mass index, waist circumference, nonalcoholic fatty liver disease, and homeostatic model assessment of IR were independently associated with hepassocin after adjusting for age, sex, high-sensitivity C-reactive protein, systolic blood pressure, high-density lipoprotein-cholesterol, log triglycerides, alanine transaminase, and the estimated glomerular filtration rate. This study provides evidence that subjects who were overweight or obese had significantly higher hepassocin levels than those with a NW. Hepassocin may be a useful biomarker in managing obesity and its related metabolic dysregulation.

原文英語
期刊BioFactors
DOIs
出版狀態接受/付印 - 一月 1 2019

指紋

Obesity
Insulin
Blood pressure
Biomarkers
Public health
Medical problems
Alanine Transaminase
Linear regression
Weights and Measures
Regression analysis
Liver
C-Reactive Protein
HDL Cholesterol
Insulin Resistance
Triglycerides
Blood Pressure
Waist Circumference
Glomerular Filtration Rate
Linear Models
Body Mass Index

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Clinical Biochemistry

引用此文

Huang, R. L., Li, C. H., Du, Y. F., Cheng, K. P., Lin, C. H., Hu, C. Y., ... Ou, H. Y. (認可的出版社/出版中). Discovery of a role of the novel hepatokine, hepassocin, in obesity. BioFactors. https://doi.org/10.1002/biof.1574

Discovery of a role of the novel hepatokine, hepassocin, in obesity. / Huang, Ru Lai; Li, Chung Hao; Du, Ye Fong; Cheng, Kai Pi; Lin, Ching Han; Hu, Che Yuan; Wu, Jin Shang; Chang, Chih Jen; Wu, Hung Tsung; Ou, Horng Yih.

於: BioFactors, 01.01.2019.

研究成果: 雜誌貢獻文章

Huang, RL, Li, CH, Du, YF, Cheng, KP, Lin, CH, Hu, CY, Wu, JS, Chang, CJ, Wu, HT & Ou, HY 2019, 'Discovery of a role of the novel hepatokine, hepassocin, in obesity', BioFactors. https://doi.org/10.1002/biof.1574
Huang, Ru Lai ; Li, Chung Hao ; Du, Ye Fong ; Cheng, Kai Pi ; Lin, Ching Han ; Hu, Che Yuan ; Wu, Jin Shang ; Chang, Chih Jen ; Wu, Hung Tsung ; Ou, Horng Yih. / Discovery of a role of the novel hepatokine, hepassocin, in obesity. 於: BioFactors. 2019.
@article{aafffa4982b740b58abaa51420a67cee,
title = "Discovery of a role of the novel hepatokine, hepassocin, in obesity",
abstract = "Obesity is a public health problem that has raised concerns worldwide and is often associated with hepatic steatosis. Hepassocin is a novel hepatokine that causes hepatic steatosis and induces insulin resistance (IR). However, the role of hepassocin in obesity remains obscure. Thus, the aim of this study was to investigate the relationship between hepassocin levels and obesity. In total, 371 subjects who had a normal weight (NW), were overweight, or were obese were enrolled. We found that hepassocin levels in subjects who were overweight (6,705 ± 1,707 pg/ml) or obese (7,335 ± 2,077 pg/ml) were significantly higher than those of subjects with a NW (5,767 ± 1,500 pg/ml) (p <.001, test for trend). A multiple linear regression analysis showed that the body-mass index, waist circumference, nonalcoholic fatty liver disease, and homeostatic model assessment of IR were independently associated with hepassocin after adjusting for age, sex, high-sensitivity C-reactive protein, systolic blood pressure, high-density lipoprotein-cholesterol, log triglycerides, alanine transaminase, and the estimated glomerular filtration rate. This study provides evidence that subjects who were overweight or obese had significantly higher hepassocin levels than those with a NW. Hepassocin may be a useful biomarker in managing obesity and its related metabolic dysregulation.",
keywords = "diabetes, hepassocin, HOMA-IR, obesity, overweight",
author = "Huang, {Ru Lai} and Li, {Chung Hao} and Du, {Ye Fong} and Cheng, {Kai Pi} and Lin, {Ching Han} and Hu, {Che Yuan} and Wu, {Jin Shang} and Chang, {Chih Jen} and Wu, {Hung Tsung} and Ou, {Horng Yih}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/biof.1574",
language = "English",
journal = "BioFactors",
issn = "0951-6433",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Discovery of a role of the novel hepatokine, hepassocin, in obesity

AU - Huang, Ru Lai

AU - Li, Chung Hao

AU - Du, Ye Fong

AU - Cheng, Kai Pi

AU - Lin, Ching Han

AU - Hu, Che Yuan

AU - Wu, Jin Shang

AU - Chang, Chih Jen

AU - Wu, Hung Tsung

AU - Ou, Horng Yih

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Obesity is a public health problem that has raised concerns worldwide and is often associated with hepatic steatosis. Hepassocin is a novel hepatokine that causes hepatic steatosis and induces insulin resistance (IR). However, the role of hepassocin in obesity remains obscure. Thus, the aim of this study was to investigate the relationship between hepassocin levels and obesity. In total, 371 subjects who had a normal weight (NW), were overweight, or were obese were enrolled. We found that hepassocin levels in subjects who were overweight (6,705 ± 1,707 pg/ml) or obese (7,335 ± 2,077 pg/ml) were significantly higher than those of subjects with a NW (5,767 ± 1,500 pg/ml) (p <.001, test for trend). A multiple linear regression analysis showed that the body-mass index, waist circumference, nonalcoholic fatty liver disease, and homeostatic model assessment of IR were independently associated with hepassocin after adjusting for age, sex, high-sensitivity C-reactive protein, systolic blood pressure, high-density lipoprotein-cholesterol, log triglycerides, alanine transaminase, and the estimated glomerular filtration rate. This study provides evidence that subjects who were overweight or obese had significantly higher hepassocin levels than those with a NW. Hepassocin may be a useful biomarker in managing obesity and its related metabolic dysregulation.

AB - Obesity is a public health problem that has raised concerns worldwide and is often associated with hepatic steatosis. Hepassocin is a novel hepatokine that causes hepatic steatosis and induces insulin resistance (IR). However, the role of hepassocin in obesity remains obscure. Thus, the aim of this study was to investigate the relationship between hepassocin levels and obesity. In total, 371 subjects who had a normal weight (NW), were overweight, or were obese were enrolled. We found that hepassocin levels in subjects who were overweight (6,705 ± 1,707 pg/ml) or obese (7,335 ± 2,077 pg/ml) were significantly higher than those of subjects with a NW (5,767 ± 1,500 pg/ml) (p <.001, test for trend). A multiple linear regression analysis showed that the body-mass index, waist circumference, nonalcoholic fatty liver disease, and homeostatic model assessment of IR were independently associated with hepassocin after adjusting for age, sex, high-sensitivity C-reactive protein, systolic blood pressure, high-density lipoprotein-cholesterol, log triglycerides, alanine transaminase, and the estimated glomerular filtration rate. This study provides evidence that subjects who were overweight or obese had significantly higher hepassocin levels than those with a NW. Hepassocin may be a useful biomarker in managing obesity and its related metabolic dysregulation.

KW - diabetes

KW - hepassocin

KW - HOMA-IR

KW - obesity

KW - overweight

UR - http://www.scopus.com/inward/record.url?scp=85074431428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074431428&partnerID=8YFLogxK

U2 - 10.1002/biof.1574

DO - 10.1002/biof.1574

M3 - Article

C2 - 31587376

AN - SCOPUS:85074431428

JO - BioFactors

JF - BioFactors

SN - 0951-6433

ER -